• About
• Links
• Contact
• Sitemap

Sitemap > Breaking Research > Psychiatric, Addictive & Sleep Disorders

• Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice.
• Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials.
• Anxiolytic effects of benzalphthalides.
• Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study.
• Screening of an endothelial cDNA library identifies the C-terminal region of Nedd5 as a novel autoantigen in systemic lupus erythematosus with psychiatric manifestations.
• The effects of curcumin on depressive-like behaviors in mice.
• Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine.
• Genetic inactivation of melanin-concentrating hormone receptor subtype 1 (MCHR1) in mice exerts anxiolytic-like behavioral effects.
• Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.
• Interaction of chiral MS-245 analogs at h5-HT6 receptors.
• QSAR study on thiazole and thiadiazole analogues as antagonists for the adenosine A1 and A3 receptors.
• Simultaneous use of thyrotropin-releasing hormone test and combined dexamethasone/corticotropine-releasing hormone test for severity evaluation and outcome prediction in patients with major depressive disorder.
• mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition.
• Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 4: 3-Alkyl-4-halo-6-nitroquipazines.
• A novel and selective monoamine oxidase B substrate.
• 5-HT1A receptor agonists modify epileptic seizures in three experimental models in rats.
• Regionally selective and dose-dependent effects of the ampakines Org 26576 and Org 24448 on local cerebral glucose utilisation in the mouse as assessed by 14C-2-deoxyglucose autoradiography.
• 4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomnia.
• Design, synthesis, and AMPA receptor antagonistic activity of a novel 6-nitro-3-oxoquinoxaline-2-carboxylic acid with a substituted phenyl group at the 7 position.
• Structure-activity studies of 3'-4'-dichloro-meperidine analogues at dopamine and serotonin transporters.
• Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
• A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study.
• Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities.
• Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.
• A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.
• Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction.
• Adamantyl cannabinoids: a novel class of cannabinergic ligands.
• Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist.
• Effects of apomorphine on rat behavior in the elevated plus-maze.
• Phenylpyrroles, a new chemolibrary virtual screening class of 5-HT7 receptor ligands.
• Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry.
• Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1.
• Indole- and indoline-based kainate analogues with antagonist activity at ionotropic glutamate receptors.
• Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia.
• 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles.
• 1-(4-Amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine derivatives as melanin-concentrating hormone receptor-1 antagonists.
• Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers.
• Altered RNA editing of serotonin 2C receptor in a rat model of depression.
• Mice lacking Dlx1 show subtype-specific loss of interneurons, reduced inhibition and epilepsy.
• Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
• Gene expression profiling in the hippocampus of learned helpless and nonhelpless rats.
• The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
• Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function.
• Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia.
• Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.
• Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study.
• Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression.
• The Texas implementation of medication algorithms update for treatment of bipolar I disorder.
• Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.
• The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder.
• Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions.
• Novel cyclic gamma-hydroxybutyrate (GHB) analogs with high affinity and stereoselectivity of binding to GHB sites in rat brain.
• The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems.
• Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats.
• Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates.
• Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine], and benztropine analogs.
• Neurochemical changes in LPA1 receptor deficient mice--a putative model of schizophrenia.
• A longitudinal analysis of memory in patients with schizophrenia.
• Non-associative learning and anxiety in rats treated with a single systemic administration of the gastrin-releasing peptide receptor antagonist RC-3095.
• Expression analysis of genes responsible for serotonin signaling in the brain.
• Effects of the competitive N-methyl-D-aspartate receptor antagonist, LY235959 [(-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid], on responding for cocaine under both fixed and progressive ratio schedules of reinforcement.
• Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species.
• Sertindole for schizophrenia.
• Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo.
• 8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
• 3-(2-Aminoethyl)pyridine analogs as alpha4beta2 nicotinic cholinergic receptor ligands.
• Nova regulates brain-specific splicing to shape the synapse.
• Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
• Neuroprotective mechanisms of curcumin against cerebral ischemia-induced neuronal apoptosis and behavioral deficits.
• A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder.
• Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
• Novel 17beta-substituted conformationally constrained neurosteroids that modulate GABA A receptors.
• Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist.
• Chronopharmacological study of antidepressants in forced swimming test of mice.
• Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
• Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.
• Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
• Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy.
• Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
• Leptin induces a novel form of NMDA receptor-dependent long-term depression.
• Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study.
• Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia.
• Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study.
• Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.
• New 5-hydroxytryptamine(1A) receptor ligands containing a norbornene nucleus: synthesis and in vitro pharmacological evaluation.
• Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.
• Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study.
• A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
• An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition.
• Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog.
• Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder.
• Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety.
• N-8-Substituted benztropinamine analogs as selective dopamine transporter ligands.
• Benzodiazepine receptor ligands. 8: synthesis and pharmacological evaluation of new pyrazolo[5,1-c] [1,2,4]benzotriazine 5-oxide 3- and 8-disubstituted: high affinity ligands endowed with inverse-agonist pharmacological efficacy.
• Identification and functional characterization of brainstem cannabinoid CB2 receptors.
• Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression.
• A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell.
• Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
• Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis.
• Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.
• Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders.
• Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication.
• Pyrazole CCK(1) receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivity.
• Kappa-opioid agonist U69593 potentiates locomotor sensitization to the D2/D3 agonist quinpirole: pre- and postsynaptic mechanisms.
• Estrogen prevents 5-HT1A receptor-induced disruptions of prepulse inhibition in healthy women.
• The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.
• Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders.
• Differences in compliance patterns across the selective serotonin reuptake inhibitors (SSRIs).
• A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
• Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children.
• Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study.
• Venlafaxine-induced urinary incontinence resolved after switching to sertraline.
• Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.
• Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice.
• Deficits in sexual and aggressive behaviors in Cnga2 mutant mice.
• Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: 1H-pyrimidin-2-one derivatives.
• Onset and persistence of depression in older people--results from a 2-year community follow-up study.
• Modulation of striatal dopamine release in vitro by agonists of the glycineB site of NMDA receptors; interaction with antipsychotics.
• The selective tachykinin neurokinin 1 (NK1) receptor antagonist, GR 205,171, stereospecifically inhibits light-induced phase advances of hamster circadian activity rhythms.
• Synthesis and structure-activity relationships of 8-azabicyclo[3.2.1]octane benzylamine NK1 antagonists.
• Anxiety and cognition in female histidine decarboxylase knockout (Hdc(-/-)) mice.
• Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
• Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
• A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics.
• Prevention of relapse in generalized anxiety disorder by escitalopram treatment.
• Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine.
• A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan.
• An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.
• Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia.
• Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course.
• A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia.
• Episodic memory-related activation in schizophrenia: meta-analysis.
• Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases.
• Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder.
• Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor.
• Selective serotonin reuptake inhibitors and suicidality in juveniles: review of the evidence and implications for clinical practice.
• Dopamine D4 receptor signaling in the rat paraventricular hypothalamic nucleus: Evidence of natural coupling involving immediate early gene induction and mitogen activated protein kinase phosphorylation.
• Evaluation of two genetic animal models in behavioral tests of anxiety and depression.
• Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells.
• Toward a reliable distinction between patients with mild cognitive impairment and Alzheimer-type dementia versus major depression.
• Generalized and specific neurocognitive deficits in prodromal schizophrenia.
• Abnormal benzodiazepine receptor function in the depressive-like behavior of diabetic mice.
• Social approach-avoidance behavior of a high-anxiety strain of rats: effects of benzodiazepine receptor ligands.
• Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia.
• Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: a 12-week, randomized, open-label study.
• Open-label trial of riluzole in generalized anxiety disorder.
• Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus.
• Expression and genetic variability of PCDH11Y, a gene specific to Homo sapiens and candidate for susceptibility to psychiatric disorders.
• Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists.
• Studies toward the discovery of the next generation of antidepressants. Part 5: 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives with dual 5-HT1A receptor and serotonin transporter affinity.
• First structure-activity relationship study on dopamine D3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamide structure.
• Use of atypical antipsychotics in refractory depression and anxiety.
• Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety.
• Prevalence, associated risks, and treatment patterns of insomnia.
• Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms.
• Striatal microinjections of interleukin-2 and rat behaviour in the elevated plus-maze.
• Synthesis and appetite suppressant activity of 1-aryloxy-2-substituted aminomethyltetrahydronaphthalenes as conformationally rigid analogues of fluoxetine.
• MCL0042: a nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity.
• Aminoalkyl phenyl sulfones--a novel series of 5-HT7 receptor ligands.
• Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.
• Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders.
• Oxytocin modulates neural circuitry for social cognition and fear in humans.
• Recombinant human nerve growth factor with a marked activity in vitro and in vivo.
• Comparative cue generalization profiles of L-838, 417, SL651498, zolpidem, CL218,872, ocinaplon, bretazenil, zopiclone, and various benzodiazepines in chlordiazepoxide and zolpidem drug discrimination.
• Opinion: NK3 receptor antagonists: the next generation of antipsychotics?
• Impact of venlafaxine on gene expression profile in lymphocytes of the elderly with major depression--evolution of antidepressants and the role of the "neuro-immune" system.
• Biochemical profile in patients with anxious depression under the treatment with serotonergic antidepressants with different mechanisms of action.
• Human QKI, a new candidate gene for schizophrenia involved in myelination.
• Ionotropic glutamate receptors and glutamate transporters are involved in necrotic neuronal cell death induced by oxygen-glucose deprivation of hippocampal slice cultures.
• Hypocretin (orexin) receptor subtypes differentially enhance acetylcholine release and activate g protein subtypes in rat pontine reticular formation.
• Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.
• BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.
• A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder.
• Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors.
• The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C.
• Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands.
• Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety.
• Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia.
• Phenyl ureas of creatinine as mGluR5 antagonists. A structure-activity relationship study of fenobam analogues.
• Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones as alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.
• Imidazo[1,2-b][1,2,4]triazines as alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.
• Effect of mirtazapine on thyroid hormones in adult patients with major depression.
• The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain.
• Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade.
• Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study.
• A double-blind, placebo-controlled study of memantine in the treatment of major depression.
• Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders.
• Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors.
• Risk of schizophrenia in people with coeliac disease, ulcerative colitis and Crohn's disease: a general population-based study.
• Chronic administration of 13-cis-retinoic acid increases depression-related behavior in mice.
• Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study.
• Migraine with and without aura: association with depression and anxiety disorder in a population-based study. The HUNT Study.
• Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients.
• Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors.
• Alterations in 5-HT1B receptor function by p11 in depression-like states.
• The effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: a 24-week continuation therapy.
• Cannabidiol monotherapy for treatment-resistant schizophrenia.
• Naltrexone and buprenorphine combination in the treatment of opioid dependence.
• The novel brain-specific tryptophan hydroxylase-2 gene in panic disorder.
• Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.
• A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome.
• cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects.
• Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
• A remote and highly conserved enhancer supports amygdala specific expression of the gene encoding the anxiogenic neuropeptide substance-P.
• Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder.
• Interaction of arylpiperazine ligands with the hydrophobic part of the 5-HT1A receptor binding site.
• Association study of serotonin 2A receptor (5-HT2A) gene with schizophrenia and suicidal behavior using systematic meta-analysis.
• Imidazo[1,2-a]pyrimidines as functionally selective GABA(A) ligands.
• Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique.
• Activation of adenosine A1 receptors reduces anxiety-like behavior during acute ethanol withdrawal (hangover) in mice.
• Serotonin and fluoxetine modulate bone cell function in vitro.
• Identification of a pharmacophore of SKCa channel blockers.
• A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer.
• Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials.
• A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania.
• Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia.
• Age-dependent measures of anxiety and cognition in male histidine decarboxylase knockout (Hdc-/-) mice.
• Identification of anxiolytic ingredients in ginseng root using the elevated plus-maze test in mice.
• Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.
• 1-Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) antagonists.
• Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial.
• A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder.
• New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram.
• Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder.
• Effects of haloperidol and clozapine on sensorimotor gating deficits induced by 5-hydroxytryptamine depletion in the brain.
• Small RNAs in human brain development and disorders.
• Comorbidity between social phobia and premature ejaculation: study on 242 males affected by sexual disorders.
• Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications.
• The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study.
• Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
• Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia.
• Quality of life and pain in premenopausal women with major depressive disorder: The POWER Study.
• Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
• Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study.
• Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study.
• An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.
• Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study.
• Inhibition of cardiac HERG potassium channels by antidepressant maprotiline.
• Leptin: a potential novel antidepressant.
• An open trial of adjunctive escitalopram in bipolar depression.
• Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.
• A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities.
• Long term outcomes from the IMPACT randomised trial for depressed elderly patients in primary care.
• Synthesis and biological activity of picobenzide (3,5-dimethyl-N-(pyridin-4-ylmethyl)benzamide) analogues as potential antipsychotic agents.
• Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals.
• The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects.
• An open-label study of tiagabine as augmentation therapy for anxiety.
• Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial.
• Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists.
• Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme.
• Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana.
• Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects.
• Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?
• Intracellular targeting of truncated secretory peptides in the mammalian heart and brain.
• Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression.
• Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.
• Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
• Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
• Clinical features of bipolar depression versus major depressive disorder in large multicenter trials.
• Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers.
• Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.
• Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants.
• Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment.
• Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
• Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis.
• Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications.
• A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins.
• Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat.
• Combined treatment with citalopram and buspirone: effects on serotonin 5-HT2A and 5-HT2C receptors in the rat brain.
• Synthesis, in vitro and in vivo evaluation of [O-methyl-11C] 2-{4-[4-(3-methoxyphenyl)piperazin-1-yl]-butyl}-4-methyl-2H-[1,2,4]-triazine-3,5-dione: a novel agonist 5-HT1A receptor PET ligand.
• Effects of acute and chronic nicotine on elevated plus maze in mice: involvement of calcium channels.
• Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine.
• Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating.
• Schizophrenia and diabetes: epidemiological data.
• Antipsychotics and the risk of diabetes: a general data review.
• Synthesis and biological evaluation of (2S)- and (2R)-2-(3'-phosphonobicyclo[1.1.1]pentyl)glycines as novel group III selective metabotropic glutamate receptor ligands.
• Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice.
• The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
• Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
• Antipsychotics in early onset Schizophrenia: Systematic review and meta-analysis.
• In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.
• Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial.
• Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse.
• An open-label study of escitalopram (Lexapro) for the treatment of 'Depression of Alzheimer's disease' (dAD).
• Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxiety.
• Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication.
• Structure-activity relationship of thiopyrimidines as mGluR5 antagonists.
• Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory.
• Forebrain glucocorticoid receptors modulate anxiety-associated locomotor activation and adrenal responsiveness.
• Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice.
• Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase.
• A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).
• Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential.
• Targeting melanocortin receptors as potential novel therapeutics.
• Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
• Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam.
• Delta opioid receptor ligands modulate anxiety-like behaviors in the rat.
• The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
• Target brain sites of the anxiolytic effect of citalopram, a selective serotonin reuptake inhibitor.
• Efficient synthesis of novel NK1 receptor antagonists: selective 1,4-addition of grignard reagents to 6-chloronicotinic acid derivatives.
• Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment.
• N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.
• Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis.
• Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test.
• Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior.
• Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.
• Three-year incidence of first-onset depressive syndrome in a population sample of older adults: the Cache County study.
• Depressive symptom deterioration in a large primary care-based elderly cohort.
• Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.
• Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.
• Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials.
• Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
• Major depression in female urinary incontinence.
• Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.
• Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
• T-type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine.
• In search of mixed anxiety-depressive disorder: a primary care study.
• Evidence that variation in the peripheral benzodiazepine receptor (PBR) gene influences susceptibility to panic disorder.
• Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
• Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial.
• Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study.
• Repeated injection of MK801: an animal model of schizophrenia?
• Proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative novel antidepressants: CRF1 and NK1 receptor antagonists.
• A regional comparison of developing diabetes among VA patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors.
• Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.
• Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects.
• Platelet-endothelial cell adhesion molecule-1 (CD31) recycles and induces cell growth inhibition on human tumor cell lines.
• Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine.
• Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
• A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
• Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials.
• Effects of OPC-14523, a combined sigma and 5-HT1a ligand, on pre- and post-synaptic 5-HT1a receptors.
• Synthesis and evaluation of N-(3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1H-indole-carboxamides as cholecystokinin antagonists.
• Effects of taurine on rat behaviors in three anxiety models.
• Maintenance treatment of major depression in old age.
• Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.
• Anxiolytic-like properties of the anandamide transport inhibitor AM404.
• Effect of initial ziprasidone dose on length of therapy in schizophrenia.
• Effect of initial ziprasidone dose on treatment persistence in schizophrenia.
• Postmarketing surveillance of suicidal adverse events with pediatric use of antidepressants.
• An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder.
• Antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial.
• Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
• Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study.
• Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey.
• Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial.
• Glucocorticoids reduce phobic fear in humans.
• Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.
• SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue.
• Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy.
• Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
• Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
• New-onset type-2 diabetes associated with atypical antipsychotic medications.
• Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial.
• Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study.
• Elevation in plasma Abeta42 in geriatric depression: a pilot study.
• Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
• Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
• Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
• Time course for antipsychotic treatment response in first-episode schizophrenia.
• The role of phospholipases A2 in schizophrenia.
• The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.
• Expression of the alpha1A-adrenergic receptor in schizophrenia.
• Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study.
• Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.
• A chemical switch for the modulation of the functional activity of higher homologues of histamine on the human histamine H3 receptor: effect of various substitutions at the primary amino function.
• A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.
• Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction?
• The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers.
• An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats.
• The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.
• Longitudinal course of depression symptoms in multiple sclerosis.
• ATC0175: an orally active melanin-concentrating hormone receptor 1 antagonist for the potential treatment of depression and anxiety.
• The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review.
• Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol.
• Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils.
• Three dimensions of clinical symptoms in elderly patients with schizophrenia: prediction of six-year cognitive and functional status.
• Risperidone versus olanzapine for schizophrenia.
• Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
• Risk factors for postpartum depression: a retrospective investigation at 4-weeks postnatal and a review of the literature.
• Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests.
• Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
• A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.
• Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine.
• L-NAME prevents anxiety-like and depression-like behavior in rats exposed to restraint stress.
• Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.
• Depression assessed over 1-year survival in patients with myocardial infarction.
• A study of the serotonin transporter in the prefrontal cortex in late-life depression and Alzheimer's disease with and without depression.
• Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
• Decreasing pain and anxiety associated with patient-activated atrial shock: a placebo-controlled study of adjunctive sedation with oral triazolam.
• High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
• Effect of acute and chronic administration of caffeine on pain-like behaviors in rats with partial sciatic nerve injury.
• Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
• Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study.
• The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat.
• Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis.
• Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
• An open-label trial of risperidone augmentation for refractory anxiety disorders.
• Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability.
• Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity.
• Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.
• Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment.
• A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder.
• Serum free Fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics.
• Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice.
• QSAR modeling of the inhibition of glycogen synthase kinase-3.
• Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis.
• Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials.
• A systematic review of modafinil: Potential clinical uses and mechanisms of action.
• Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.
• A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.
• Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data.
• High-dose aripiprazole in treatment-resistant schizophrenia.
• Cognitive impairment and depression outcomes in the IMPACT study.
• The presence of background dopamine signal converts long-term synaptic depression to potentiation in rat prefrontal cortex.
• Pharmacological stimulation of group ii metabotropic glutamate receptors reduces cocaine self-administration and cocaine-induced reinstatement of drug seeking in squirrel monkeys.
• Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.
• Arylpiperazines with N-acylated amino acids as 5-HT1A receptor ligands.
• Synthesis and SAR of novel histamine H3 receptor antagonists.
• Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety.
• Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
• Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood.
• alpha(4)beta (2) Nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating.
• Cyclobutane derivatives as potent NK1 selective antagonists.
• Is early- and late-onset depression after acute myocardial infarction associated with long-term survival in older adults? A population-based study.
• Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation.
• Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression.
• In the aftermath of CATIE: how should administrators value atypical antipsychotic medications?
• Development and validation of an Overall Anxiety Severity And Impairment Scale (OASIS).
• Elevated T-maze evaluation of anxiety and memory effects of NMDA/glycine-B site ligands injected into the dorsal periaqueductal gray matter and the superior colliculus of rats.
• Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
• QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine.
• Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.
• Transfer of reboxetine into breastmilk, its plasma concentrations and lack of adverse effects in the breastfed infant.
• Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
• A controlled longitudinal 5-year follow-up study of children at high and low risk for panic disorder and major depression.
• Why do physicians switch from one antipsychotic agent to another? The "physician drug stereotype".
• Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia.
• A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.
• Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies.
• A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.
• Differentiation of hippocampal stem cells into functional neurons: evolving our understanding of monoamine oxidase-A inhibition.
• Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway.
• Both alpha2 and alpha3 GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in the conditioned emotional response paradigm.
• Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence.
• Suppression of P-glycoprotein expression by antipsychotics trifluoperazine in adriamycin-resistant L1210 mouse leukemia cells.
• Binding of methoxy-substituted N1-benzenesulfonylindole analogs at human 5-HT6 serotonin receptors.
• SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
• Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia.
• Nitric oxide donor molsidomine attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801.
• A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
• Behavioral characterization of CD26 deficient mice in animal tests of anxiety and antidepressant-like activity.
• Alpha 2A-adrenoceptors enhance the serotonergic effects of fluoxetine.
• The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials.
• Reduction in repeated ethanol-withdrawal-induced anxiety-like behavior by site-selective injections of 5-HT(1A) and 5-HT (2C) ligands.
• Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors.
• Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial.
• An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
• The synthesis and SAR of 2-arylsulfanylphenyl-1-oxyalkylamino acids as GlyT-1 inhibitors.
• Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial.
• Role of IL-1 in poststroke depressive-like behavior in mice.
• Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.
• Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder.
• Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.
• Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort.
• TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) exhibits anxiolytic-like activity in a marble-burying assay in mice.
• Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
• Effects of milnacipran in animal models of anxiety and memory.
• Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats.
• High-throughput screening for the discovery of inhibitors of fatty acid amide hydrolase using a microsome-based fluorescent assay.
• Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
• A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
• Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial.
• Atypical anxiolytic-like response to naloxone in benzodiazepine-resistant 129S2/SvHsd mice: role of opioid receptor subtypes.
• Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice.
• Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial.
• Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia.
• Galantamine improves cognition in schizophrenic patients stabilized on risperidone.
• Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test.
• Differential effects of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) on 5-hydroxytryptamine(2C) receptor-mediated responses.
• Hippocampal neuropathology of diabetes mellitus is relieved by estrogen treatment.
• Hydrazides of clozapine: a new class of D1 dopamine receptor subtype selective antagonists.
• The antidepressant -like effects of delta-opioid receptor agonists.
• Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.
• The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine.
• Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
• Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder.
• A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents.
• Prevalence of the metabolic syndrome among patients receiving clozapine.
• Anxiolytic-like effects of the selective metabotropic glutamate receptor 5 antagonist MPEP after its intra-amygdaloid microinjection in three different non-conditioned rat models of anxiety.
• Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression.
• Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
• Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
• Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
• Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.
• Synthesis and anxiolytic activity of 1-phenyl-2-(4-aryl-1,3,4,5-tetrahydropyrido[2,3-b][1 ,4]diazepin-2-ylidene)-ethanone.
• Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression.
• Differential role of 5-HT1A and 5-HT1B receptors on the antinociceptive and antidepressant effect of tramadol in mice.
• Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice.
• Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
• Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.
• The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers.
• IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors.
• The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats.
• Facilitating antidepressant-like actions of estrogens are mediated by 5-HT1A and estrogen receptors in the rat forced swimming test.
• Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
• Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors.
• SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: Evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brain.
• Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
• Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
• Mania associated with interferon alpha2b treatment.
• Gabapentin treatment of neurogenic overactive bladder.
• Postpartum depression: a randomized trial of sertraline versus nortriptyline.
• Mood and neuropsychological changes in women with midlife depression treated with escitalopram.
• Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment.
• An open prospective study of zonisamide in acute bipolar depression.
• Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
• Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat.
• Schizoaffective disorders are psychotic mood disorders; there are no schizoaffective disorders.
• A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects.
• Second-generation antidepressant discontinuation and depressive relapse in adult patients with bipolar depression: results of a retrospective database analysis.
• Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
• Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study.
• Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial.
• Effects of (-)stepholidine in animal models for schizophrenia.
• Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects.
• An open label follow-up study on amisulpride in the add-on treatment of bipolar I patients.
• Add-on quetiapine for bipolar depression: a 12-month open-label trial.
• A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants.
• Dopamine D2-like receptors and the antidepressant response.
• A study of the involvement of melanin-concentrating hormone receptor 1 (MCHR1) in murine models of depression.
• Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain.
• The ampakine CX546 restores the prepulse inhibition and latent inhibition deficits in mGluR5-deficient mice.
• SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
• Escitalopram in the treatment of anxiety symptoms associated with depression.
• A case series: evaluation of the metabolic safety of aripiprazole.
• Co-administration of a nitric oxide synthase inhibitor and melatonin exerts an additive antidepressant-like effect in the mouse forced swim test.
• 3-[5-(4,5-dihydro-1H-imidazol-2-yl)-furan-2-yl]phenylamine (Amifuraline), a promising reversible and selective peripheral MAO-A inhibitor.
• Cardiovascular changes associated with venlafaxine in the treatment of late-life depression.
• Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.
• Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania.
• A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment.
• Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse.
• Structure-activity relationship of wedelolactone analogues: structural requirements for inhibition of Na+, K+ -ATPase and binding to the central benzodiazepine receptor.
• Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding?
• Predictors of relapse in a prospective study of fluoxetine treatment of major depression.
• SAR study of 1-aryl-4-(phenylarylmethyl)piperazines as ligands for both dopamine D2 and serotonin 5-HT1A receptors showing varying degrees of (Ant)agonism. Selection of a potential atypical antipsychotic.
• The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats.
• CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.
• N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II.
• N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.
• A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.
• Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex.
• Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism.
• Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
• A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
• 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists.
• Atypical antipsychotics related metabolic syndrome in bipolar patients.
• Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches.
• Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.
• The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors.
• Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
• A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study.
• Synthesis and activity of a new class of dual acting norepinephrine and serotonin reuptake inhibitors: 3-(1H-indol-1-yl)-3-arylpropan-1-amines.
• Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
• Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial.
• Do the ABCS 135 short cognitive screen and its subtests discriminate between normal cognition, mild cognitive impairment and dementia?
• Reduced serotonin-1A receptor binding in social anxiety disorder.
• COPI-mediated retrograde transport is required for efficient gamma-secretase cleavage of the amyloid precursor protein.
• Nonviral gene transfer of hepatocyte growth factor attenuates neurologic injury after spinal cord ischemia in rabbits.
• Tails of the unexpected - an atypical receptor for the chemokine RANTES/CCL5 expressed in brain.
• Modulation of Abeta42 low-n oligomerization using a novel yeast reporter system.
• The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
• Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study.
• Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
• Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction.
• Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Synthesis, pharmacological, and molecular modeling studies.
• Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging.
• Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases.
• Altered PPARgamma expression and activation after transient focal ischemia in rats.
• Pain hypersensitivity in rats with experimental autoimmune neuritis, an animal model of human inflammatory demyelinating neuropathy.
• New multipotent tetracyclic tacrines with neuroprotective activity.
• Activation, internalization, and recycling of the serotonin 2A receptor by dopamine.
• BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology.
• Possible mechanisms of neurodegeneration in schizophrenia.
• R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor.
• Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice.
• A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis.
• Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones.
• Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit.
• Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response.
• The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.
• Leukotriene D4 induces brain edema and enhances CysLT2 receptor-mediated aquaporin 4 expression.
• Iptakalim protects PC12 cell against H2O2-induced oxidative injury via opening mitochondrial ATP-sensitive potassium channel.
• Improved regional cerebral blood flow is important for the protection seen in a mouse model of late phase ischemic preconditioning.
• Characterization of KIAA0513, a novel signaling molecule that interacts with modulators of neuroplasticity, apoptosis, and the cytoskeleton.
• Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy.
• CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis.
• Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury.
• Anxiolytic effect of agmatine in rats and mice.
• Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists.
• Effect of chronic angiotensin converting enzyme inhibition on spatial memory and anxiety-like behaviours in rats.
• Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report.
• Costs and consequences of enhanced primary care for depression: systematic review of randomised economic evaluations.
• Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review.
• Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?
• Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials.
• Long-term memory deficits in Pavlovian fear conditioning in Ca2+/calmodulin kinase kinase alpha-deficient mice.
• Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
• Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
• Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.
• Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
• Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
• The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
• A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice.
• Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior.
• Antidepressants enhance the antinociceptive effects of carbamazepine in the acetic acid-induced writhing test in mice.
• Acute tryptophan depletion alters gastrointestinal and anxiety symptoms in irritable bowel syndrome.
• Behavioral alterations in mice lacking the translation repressor 4E-BP2.
• Neuromedin U receptor 2-deficient mice display differential responses in sensory perception, stress, and feeding.
• Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin.
• Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogues for in vivo investigation.
• Dopamine/serotonin receptor ligands. 13: Homologization of a benzindoloazecine-type dopamine receptor antagonist modulates the affinities for dopamine D(1)-D(5) receptors.
• Bombesin receptors as a novel anti-anxiety therapeutic target: BB1 receptor actions on anxiety through alterations of serotonin activity.
• Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
• Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.
• WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
• A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
• Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition.
• Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats.
• An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha protects against methamphetamine-induced rewarding effects and sensitization.
• Effect of GNTI, a kappa opioid receptor antagonist, on MK-801-induced hyperlocomotion and stereotypy in mice.
• Role of voltage-gated L-type Ca2+ channel isoforms for brain function.
• The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis.
• A novel therapeutic approach to depression via supplement with tyrosine hydroxylase.
• Hepatitis C virus infection and neurocognitive function.
• Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite.
• Neuropsychological impairment and decreased regional cerebral blood flow by interferon treatment in patients with chronic hepatitis: a preliminary study.
• The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy.
• Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: the cerebral basis for impaired control of food intake in metabolic syndrome?
• Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives.
• Synthesis of 8-thiabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.
• Effects of mood stabilizers on the disruption of prepulse inhibition induced by apomorphine or dizocilpine in mice.
• Inhibition of astroglial inwardly rectifying Kir4.1 channels by a tricyclic antidepressant, nortriptyline.
• Inhibition of G protein-activated inwardly rectifying K+ channels by the antidepressant paroxetine.
• Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats.
• Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.
• Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning.
• Depression induces bone loss through stimulation of the sympathetic nervous system.
• The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients.
• Modafinil and unconstrained motor activity in schizophrenia: double-blind crossover placebo-controlled trial.
• Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
• 5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.
• Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
• Microglia: a cellular vehicle for CNS gene therapy.
• The striatal-enriched protein tyrosine phosphatase gates long-term potentiation and fear memory in the lateral amygdala.
• Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
• A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase.
• Studies towards the identification of a new generation of atypical antipsychotic agents.
• Anxiety sensitivity within the anxiety disorders: disorder-specific sensitivities and depression comorbidity.
• Effect of BD 1047, a sigma1 receptor antagonist, in the animal models predictive of antipsychotic activity.
• Antidepressant-like effects of baclofen and LY367385 in the forced swim test in rats.
• The persistence of depression score.
• The novel anxiolytic ELB139 displays selectivity to recombinant GABA(A) receptors different from diazepam.
• Design, synthesis, and SAR analysis of novel selective sigma1 ligands.
• Adverse effects of risperidone on spatial working memory in first-episode schizophrenia.
• Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis.
• A novel azaindolizinone derivative ZSET1446 (spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one) improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2.
• Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
• Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.
• A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
• Effect of the beta3 adrenoceptor agonist CL 316243 on hypothalamic 5-HT synthesis and suppression of REM sleep in the rat.
• Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR.
• Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
• Central alpha1-adrenergic system in behavioral activity and depression.
• Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats.
• Non-steroidal anti-inflammatory drugs and the risk of psychosis.
• Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain.
• Antidepressant-induced inhibition of genital vascular responses is reversed by vardenafil in female rabbits.
• Associations between Chlamydophila infections, schizophrenia and risk of HLA-A10.
• Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior.
• Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents.
• Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys.
• Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain.
• A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania.
• A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
• Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study.
• Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
• Dual serotonin transporter/histamine H3 ligands: Optimization of the H3 pharmacophore.
• Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.
• Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice.
• The role of delta opioid receptors in the anxiolytic actions of benzodiazepines.
• The protective effect of frontal cortex dehydroepiandrosterone in anxiety and depressive models in mice.
• Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
• ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies.
• Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
• Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder.
• Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
• Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
• A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
• Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine.
• 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats.
• Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness.
• Insulin protects against stress-induced impairments in water maze performance.
• In vivo and in vitro measurement of brain phosphodiesterase 4 in rats after antidepressant administration.
• Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis.
• Fluoxetine is not effective in the treatment of post-stroke fatigue: a double-blind, placebo-controlled study.
• Synthesis of novel quinolone and quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)amides: a late-stage diversification approach to potent 5HT1B antagonists.
• The effects of the mGluR5 antagonist MPEP and the mGluR2/3 antagonist LY341495 on rats' performance in the 5-choice serial reaction time task.
• Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors.
• 3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors.
• The effect of intrahippocampal injection of group II and III metobotropic glutamate receptor agonists on anxiety; the role of neuropeptide Y.
• Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
• Acute time to response in the Treatment for Adolescents with Depression Study (TADS).
• Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS).
• Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).
• Treatment for Adolescents with Depression Study (TADS): safety results.
• Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.
• The rate of conversion of mild cognitive impairment to dementia: predictive role of depression.
• Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.
• 5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation.
• Prevalence of psychiatric disorders across Latino subgroups in the United States.
• Expression analysis of actin-related genes as an underlying mechanism for mood disorders.
• Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.
• Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.
• GABAA but not GABAB receptors in the rostral anterior cingulate cortex selectively modulate pain-induced escape/avoidance behavior.
• Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain.
• In vivo administration of D609 leads to protection of subsequently isolated gerbil brain mitochondria subjected to in vitro oxidative stress induced by amyloid beta-peptide and other oxidative stressors: relevance to Alzheimer's disease and other oxidative stress-related neurodegenerative disorders.
• Beyond remission: rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study.
• Human and economic burden of generalized anxiety disorder.
• A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.
• Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands.
• Design and synthesis of novel derivatives of the muscarinic agonist tetra(ethylene glycol)(3-methoxy-1,2,5-thiadiazol-4-yl) [3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl] ether (CDD-0304): effects of structural modifications on the binding and activity at muscarinic receptor subtypes and chimeras.
• Heat shock protein 60 or 70 activates nitric-oxide synthase (NOS) I- and inhibits NOS II-associated signaling and depresses the mitochondrial apoptotic cascade during brain stem death.
• A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
• Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
• Effectiveness of switching antipsychotic medications.
• Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
• Receptor-based pharmacophores for serotonin 5-HT7R antagonists-implications to selectivity.
• Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray.
• Obestatin improves memory performance and causes anxiolytic effects in rats.
• A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life.
• Beta-blockers and depression after myocardial infarction: a multicenter prospective study.
• Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study.
• Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype 1.
• Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse.
• Agomelatine in the treatment of seasonal affective disorder.
• Behavioral evaluation of mice deficient in GABA(B(1)) receptor isoforms in tests of unconditioned anxiety.
• Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.
• Anxiolytic-like effect of 5-HT(2) ligands and benzodiazepines co-administration: comparison of two animal models of anxiety (the four-plate test and the elevated plus maze).
• Sodium channel blockade may contribute to the analgesic efficacy of antidepressants.
• Long-term effects of antidepressants on cognition in patients with Alzheimer's disease.
• Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study.
• Quinazoline and benzimidazole MCH-1R antagonists.
• Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein.
• 5-HT(1A) receptors in stress-induced cardiac changes: a possible link between mental and cardiac disorders.
• Investigating gene-to-behavior pathways in psychiatric disorders: the use of a comprehensive behavioral test battery on genetically engineered mice.
• Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists.
• Rational design, synthesis, and structure-activity relationship of benzoxazolones: new potent mglu5 receptor antagonists based on the fenobam structure.
• Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.
• Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial.
• A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
• Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition.
• A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.
• Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial.
• Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram.
• Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.
• A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment.
• Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.
• Effect of GABAergic ligands on the anxiolytic-like activity of DOI (a 5-HT(2A/2C) agonist) in the four-plate test in mice.
• Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists.
• Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs.
• Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis.
• Acute bipolar mani